Strategic Acquisition Excellos recently sold assets to OrganaBio and expanded facilities to San Diego, signaling a strategic pivot and potential collaboration opportunities in West Coast cell processing, cryopreservation, and CDMO services for seamless scale-up.

Scale and Capabilities Five ISO 7 cGMP cleanroom suites and a full-service CDMO with donor-derived material access position Excellos to support autologous and allogeneic therapies from preclinical to late-stage development, presenting a strong partner for end-to-end manufacturing needs.

Donor Pool Advantage Rooted in the San Diego Blood Bank with access to a diverse donor pool, Excellos offers unique material sourcing and risk mitigation for cell therapy programs, appealing to sponsors requiring reliable starting material and characterization.

Strategic Partnerships Past and ongoing collaborations with industry players and events highlight visibility and credibility; potential opportunities exist to co-develop process improvements or leverage Akadeum Life Sciences and similar partners for enhanced cell isolation and manufacturing efficiency.

Global Market Reach Although based in San Diego, Excellos serves global customers and focuses on preclinical to phase II/III programs with clear scale-up pathways, making it a fit for sponsors seeking cross-border CDMO support and international regulatory readiness.